Somatic ATM loss-of-function in PDAC: limited evidence; platinum sensitivity may be enhan...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ATM-SOMATIC-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | ATM somatic loss-of-function |
| Disease | DIS-PDAC |
| ESCAT tier | IIA |
| Recommended combinations | FOLFIRINOX (platinum-based), olaparib maintenance off-label |
| Evidence summary | Somatic ATM loss-of-function in PDAC: limited evidence; platinum sensitivity may be enhanced. PARPi off-label only. ESCAT IIA / OncoKB Level 3A. |
Notes
Reflex germline testing recommended.
Used By
No reverse references found in the YAML corpus.